Increased risk of epilepsy in patients registered in the Swedish Dementia Registry.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
01 2020
Historique:
received: 09 04 2019
accepted: 15 07 2019
pubmed: 23 7 2019
medline: 29 12 2020
entrez: 23 7 2019
Statut: ppublish

Résumé

Data on epilepsy in dementia, particularly on its risk factors, are scarce. Confounding comorbidities and the rising incidence of epilepsy in older age have hampered studies in this field. The occurrence and risk factors for epilepsy in the Swedish Dementia Registry (SveDem), a large cohort of patients with dementia, have been examined. Information on epilepsy and seizure-related diagnoses, comorbidities and survival were extracted for all individuals in SveDem (n = 81 192) and three randomly selected age- and gender-matched controls from the population register, excluding all with a dementia diagnosis (n = 223 933). The risk of epilepsy following dementia diagnosis was estimated with Kaplan-Meier curves, and Cox proportional hazard modelling was used to identify risk factors and adjust for comorbidities. A diagnosis of epilepsy was found more frequently amongst dementia patients [4.0%, 95% confidence interval (CI) 3.8-4.1] than controls (1.9%, 95% CI 1.9-2.0). The risk of incident epilepsy after dementia was 2.1% (95% CI 1.9-2.3) at 5 years and 4.0% (95%CI 3.4-4.6) at 10 years, compared to 0.8% (95% CI 0.8-0.8) and 1.6% (95% CI 1.4-1.8) respectively for controls. The risk was greatest for early-onset Alzheimer's disease. In multivariate analysis, dementia was associated with a hazard ratio of 2.52 (95% CI 2.31-2.74) for epilepsy. Young age, male sex, stroke, brain trauma, brain tumour and low Mini-Mental State Examination score significantly increased the risk. Dementia, particularly young-onset Alzheimer's disease, increases the risk of subsequent epilepsy. Further studies are needed to determine optimal management and the impact of epilepsy on prognosis.

Sections du résumé

BACKGROUND AND PURPOSE
Data on epilepsy in dementia, particularly on its risk factors, are scarce. Confounding comorbidities and the rising incidence of epilepsy in older age have hampered studies in this field. The occurrence and risk factors for epilepsy in the Swedish Dementia Registry (SveDem), a large cohort of patients with dementia, have been examined.
METHODS
Information on epilepsy and seizure-related diagnoses, comorbidities and survival were extracted for all individuals in SveDem (n = 81 192) and three randomly selected age- and gender-matched controls from the population register, excluding all with a dementia diagnosis (n = 223 933). The risk of epilepsy following dementia diagnosis was estimated with Kaplan-Meier curves, and Cox proportional hazard modelling was used to identify risk factors and adjust for comorbidities.
RESULTS
A diagnosis of epilepsy was found more frequently amongst dementia patients [4.0%, 95% confidence interval (CI) 3.8-4.1] than controls (1.9%, 95% CI 1.9-2.0). The risk of incident epilepsy after dementia was 2.1% (95% CI 1.9-2.3) at 5 years and 4.0% (95%CI 3.4-4.6) at 10 years, compared to 0.8% (95% CI 0.8-0.8) and 1.6% (95% CI 1.4-1.8) respectively for controls. The risk was greatest for early-onset Alzheimer's disease. In multivariate analysis, dementia was associated with a hazard ratio of 2.52 (95% CI 2.31-2.74) for epilepsy. Young age, male sex, stroke, brain trauma, brain tumour and low Mini-Mental State Examination score significantly increased the risk.
CONCLUSIONS
Dementia, particularly young-onset Alzheimer's disease, increases the risk of subsequent epilepsy. Further studies are needed to determine optimal management and the impact of epilepsy on prognosis.

Identifiants

pubmed: 31330091
doi: 10.1111/ene.14043
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-135

Subventions

Organisme : Västra Götaland ALF
Pays : International
Organisme : Swedish Society of Medicine
Pays : International
Organisme : Swedish Society of Medical Research
Pays : International
Organisme : Linnea and Josef Carlsson Foundation
Pays : International
Organisme : Göteborg Medical Society
Pays : International
Organisme : Magnus Bergvall Foundation
Pays : International

Informations de copyright

© European Academy of Neurology 2019.

Références

Burman J, Zelano J. Epilepsy in multiple sclerosis: a nationwide population-based register study. Neurology 2017; 89: 2462-2468.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521.
Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727-730.
Subota A, Pham T, Jette N, Sauro K, Lorenzetti D, Holroyd-Leduc J. The association between dementia and epilepsy: a systematic review and meta-analysis. Epilepsia 2017; 58: 962-972.
Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009; 66: 992-997.
Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer's disease or vascular dementia: a population-based nested case-control analysis. Epilepsia 2013; 54: 700-707.
Pandis D, Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr 2012; 12: 184-187.
Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010; 133: 1143-1154.
Religa D, Fereshtehnejad SM, Cermakova P, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS One 2015; 10: e0116538.
Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011; 52(Suppl 7): 2-26.
Sveinsson O, Andersson T, Carlsson S, Tomson T. The incidence of SUDEP: a nationwide population-based cohort study. Neurology 2017; 89: 170-177.
Annegers JF. Epilepsy. Neuroepidemiology From Principles to Practice. Oxford University Press: New York, 2004: 303-318.
Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative incidence of seizures and myoclonus in Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis 2017; 60: 211-223.
Bell JS, Lonnroos E, Koivisto AM, et al. Use of antiepileptic drugs among community-dwelling persons with Alzheimer's disease in Finland. J Alzheimers Dis 2011; 26: 231-237.
Gruntz K, Bloechliger M, Becker C, et al. Parkinson disease and the risk of epileptic seizures. Ann Neurol 2018; 83: 363-374.
Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 368-372.
McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992; 33: 657-660.
Mendez MF, Catanzaro P, Doss RC, Arguello R, Frey WH 2nd. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994; 7: 230-233.
Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435-440.
Reyes-Marin KE, Nunez A. Seizure susceptibility in the APP/PS1 mouse model of Alzheimer's disease and relationship with amyloid beta plaques. Brain Res 2017; 1677: 93-100.
Garcia-Cabrero AM, Guerrero-Lopez R, Giraldez BG, et al. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 2013; 58: 200-208.
Garcia-Ptacek S, Modeer IN, Kareholt I, et al. Differences in diagnostic process, treatment and social support for Alzheimer's dementia between primary and specialist care: results from the Swedish Dementia Registry. Age Ageing 2017; 46: 314-319.
Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363: 1184-1186.
Zelano J, Larsson D, Kumlien E, Asberg S. Pre-stroke seizures: a nationwide register-based investigation. Seizure 2017; 49: 25-29.

Auteurs

J Zelano (J)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

F Brigo (F)

Department of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy.
Division of Neurology, 'Franz Tappeiner' Hospital, Merano, Italy.

S Garcia-Patek (S)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
Internal Medicine, Section for Neurology, Södersjukhuset, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH